Congratulations @iOnctura on the eu80m funding round. We are really thrilled to see this impressive Series B funding. Excited to have been part of your journey since 2017 . Here’s to many more milestones ahead on the journey to helping cancer patients.
#OnMyHorizonhttps://lnkd.in/eY8nnQ3y
@Merck Group, @M Ventures, @Inkef, @Vi Partners, @Schroders, @3B Future Health Fund I & II, @Roel Bulthuis, @Syncona Limited, @Catherine Pickering, @Lars van Der Veen, @Cancer Research Horizons
🚀 Exciting News: AOA Dx Closes $17M Funding Round Led by Good Growth Capital 🚀
I am thrilled to announce that AOA Dx has secured an oversubscribed $17 million funding round, with Good Growth Capital at the helm and participation from leading investors like RH Capital, Y Combinator, Astia, Adaptive Capital Partners, Gore Range Capital, LongeVC, The Helm, VU Venture Partners, FemHealth Ventures, CANCER FUND and strategic diagnostics including Labcorp Venture Fund.
Let's take a moment to reflect on the challenges faced by women's health in the world of venture funding. Shockingly, only a mere 3% of healthcare venture funding is dedicated to women's health, leaving a critical gap in addressing the unique healthcare needs of women. Our successful funding round is not only a testament to the extraordinary work we are doing but also a beacon of hope for women's health innovation.
Ovarian cancer has some of the lowest survival rates among cancers, which is a stark reminder of the urgent need for innovative solutions. At AOA Dx, we are on a mission to change this narrative. We're pioneering groundbreaking work with novel biomarkers known as tumor marker gangliosides. These biomarkers hold the potential to transform early detection.
Our commitment to innovation doesn't stop there. We are proud to be the first in the industry to explore this novel biology, developing ganglioside-based liquid biopsy diagnostic tests. This cutting-edge technology has the potential to revolutionize the way we diagnose cancer, and we’re excited to continue building our platform with this capital injection.
I am incredibly passionate about this mission. The work we do at AOA is not just a job; it's a calling. It's about improving the lives of countless women and making a lasting impact on healthcare.
I want to extend a heartfelt thank you to my exceptional team and dream team co-founders Alexander Fisher and Anna Milik Jeter. Your hard work, dedication, and unwavering commitment have brought us to this pivotal moment. Together, we are pioneering change in women's health, and I can't wait to see the incredible strides we'll make in the future. 🌟
And if you’re looking to join a fast-growing, mission-driven team, please reach out!
🎉 We are proud to announce we have just closed an oversubscribed $17 million investment round, bringing our total funding to date to $24 Million. This round was led by Good Growth Capital with participation from industry leading investors including RH Capital, Y Combinator, Astia, Adaptive Capital Partners, Gore Range Capital, LongeVC, The Helm, VU Venture Partners, FemHealth Ventures, CANCER FUND along with strategic diagnostic investors, including Labcorp Venture Fund!
We are immensely grateful for the support and belief from our partners.
At AOA Dx, our journey began with a vision to bridge the gap in healthcare disparities for women. Ovarian cancer has taken too many lives, and we're here to change that through the power of novel biomarkers: tumor marker gangliosides. For decades women have been neglected in research, data and innovation. This funding will bring us one step closer to developing the first early detection test for ovarian cancer, and further develop our GlycoLocate™ platform into various new cancer areas.
We extend our heartfelt gratitude to our team - your dedication & commitment have brought us to this point.
As we continue to grow AOA, we will be hiring talented scientists who share a passion for creating a better future for cancer patients! Please reach out to us to learn more.
Thank you Anna Brown at Endpoints News for sharing our story!
#oviariancancer#womenshealth#cancer
This year at Provectus Therapeutics, we have taken a monumental leap forward with the launch of our pioneering product, the Single-AI Chip. This cutting-edge tool is unlocking new possibilities, enabling researchers to isolate, cultivate, and analyze single cells with unparalleled precision and efficiency—a breakthrough made possible through our collaboration with Provectus.AI. Single-AI Chip is not just a product; it's a beacon revealing the intricate variations in drug resistance among individual cells, a critical step in understanding and combating cancer's complexity.
As we look to the future, our resolve is unwavering. We are dedicated to pushing the boundaries of Precision Oncology Research, accelerating Early Drug Development and tailor Personalized Cancer Treatment for all patients.
We are redefining the landscape of cancer care.
Join us as we continue to break new ground in this vital field. Together, we'll turn the vision of personalized treatment into a reality for cancer patients around the globe.
#Innovation#CancerCare#PersonalizedMedicine#SingleAIChip#PrecisionOncology#FutureIsNow
Sticking to my promise being more active on socials and announcing the next big thing - LongeVC's portfolio companies 17$ million oversubscribed fundraise. Boston-based biotech company AOA Dx joined forces with us back in 2022 to re-design the early ovarian cancer diagnostics potentially saving millions of lives. And what started from seed investment, today stands as well-backed company with several heavy-weight institutional investors joining.
Check out the article to find out more:
https://lnkd.in/d7PCC4Nq
The next worthy-announcment coming out pretty soon.
🎉 Exciting News! 🎉
We are thrilled to announce that GlycoTherapeutics and chiron have been awarded the prestigious MIT Zuid-Nederland R&D subsidy! This grant, amounting to €700000+, will propel our joint project aimed at revolutionizing cancer therapy research.
Our project focuses on developing and validating the innovative µMass microplate, a groundbreaking technology that enhances the preclinical testing of anti-cancer therapies. By creating more realistic testing conditions, this technology promises to improve the reliability of preclinical results, ultimately accelerating the development of effective cancer treatments.
With this support, we are poised to make significant strides in cancer research, reducing the time and cost involved in bringing new therapies to market. This project not only aligns with but also contributes to the broader mission of improving health and extending lives, as outlined in the Dutch Knowledge and Innovation Agenda (KIA) for Health and Care.
Stay tuned for updates as we embark on this exciting journey towards better cancer treatments! Together, we can make a difference.
#CancerResearch#BiotechInnovation#MITZuid#Healthcare#Oncology#GlycoTherapeutics#chiron#InnovationInScience#GrantAward#Biotechnology
Great news! Our CEO, Sean A. MacDonald, will be participating in the highly anticipated LSX World Congress, taking place this April 29-30 in London, UK!
Don't miss Sean'presentation on Monday as he will share Domain Therapeutics' exciting advancements in precision medicine for cancer treatment.
At Domain, we're not just pioneering innovative therapies. We're redefining what's possible in the fight against cancer. Through our unwavering commitment to leveraging G Protein-Coupled Receptors (GPCRs) in immuno-oncology, we unlock new possibilities to beat resistance and defeat cancer.
If you'll be participating in this premier gathering of industry leaders and investors, don't miss this valuable opportunity to connect with Sean and discuss Domain Therapeutics' very hot targets and our innovative approach to cancer therapy.
Let's ignite conversations, forge partnerships, and drive global innovation in healthcare together. See you at LSX - partnering for Life Science eXecutives World Congress!
#PrecisionMedicine#Immunooncology#Biotech#Innovation#Fundraising
That’s almost it for another year at #ASCO2024.
As always, it’s been a privilege to speak with peers across academia and industry and see the remarkable progress being made in the fight against cancer.
It has been especially gratifying to see the fruit of AstraZeneca’s recent acquisitions and partnerships.
In cell therapy, exciting data from our collaboration with AbelZeta were on display, showing the potential of our CAR-T armouring platform in solid tumours, and Neogene Therapeutics shared the first preclinical data on their pioneering TCR-T platform. There’s still some way to go for the industry to deliver on the full potential of cell therapy, particularly in solid tumours, but our data at ASCO illustrates the power of business development and collaboration to help us get there.
In other areas, antibody-drug conjugate data at ASCO shows the power of deals and partnerships to bring innovative assets to more people living with cancer.
Finally, data from our late-stage pipeline continued to show the strength and breadth of AstraZeneca’s oncology portfolio, across immuno-oncology, tumour drivers and resistance mechanisms and antibody-drug conjugates. Our ongoing R&D progress combined with our strategic partnerships brings us closer to delivering on our ambition to eliminate cancer as a cause of death.
It’s been a busy but thoroughly enjoyable few days, with many promising discussions and connections to build on over the coming months.
#BusinessDevelopment#Oncology#innovation
What’s the difference between traditional bispecifics and our unique Bi-Cygni® approach?
Unlike other bispecifics, Bi-Cygni® targets two different antigens on the same cancer cell.
As Tiffany Thorn, Chief Executive Officer of BiVictriX Therapeutics plc, explained in a recent interview, “We’re not aware of anybody else that’s working on this particular concept – we designed the ADC so that they’re able to truly discriminate cancer cells from healthy cells. So basically, the drug only binds to and releases the payload in the cancer cells.”
Why is this important? Because it allows us to create more specific therapeutics that target the cancer, not the patient. Our preclinical safety data for our lead candidate, BVX001, backs this up, showing favourable safety compared with the current ADC therapy (Mylotarg) for acute myeloid leukaemia. https://lnkd.in/eM_ggF4k
Check out the Labiotech.eu article to learn more about the story behind our Bi-Cygni® approach: https://lnkd.in/dz26cTpV
And head to our website to learn more about our science: https://lnkd.in/eBHU7BJH#ADC#AML#Leukaemia#drugdevelopment#antibodytherapeutics#immunotherapy#Biotech#pipeline#antibodytherapeutics#oncology
I help biotechs successfully conduct FDA-compliant trials, saving them 70% on costs 💊 ▸ High-Quality Research ▸ Up to 43.5% Aus R&D Grant ▸ No IND needed ▸ 8 Weeks Avg Startup ▸ FDA Expertise
🔬 Enhancing Cancer Research at ASCO with iNGENū! 🔬
As the #ASCO24 meeting approaches, iNGENū is poised to assist oncology-focused companies in overcoming the complexities of clinical trials and regulatory landscapes.
We are dedicated to providing transformative solutions that streamline research, making cutting-edge cancer treatments more accessible and effective.
🌟 What iNGENū CRO Offers:
Cost Efficiency: Dramatically reduce the costs of oncology trials, enabling more research with the same resources.
Regulatory Expertise: Benefit from our deep understanding of FDA regulations to accelerate your path to market.
Strategic Australian Advantages: Leverage our capabilities to take advantage of fast-track processes and significant R&D tax incentives for quicker trial advancement.
👥 We are enthusiastic about partnering with leaders in oncology.
Let’s explore how our innovative approaches can support your clinical and regulatory strategies for cancer research.
#ASCO#Oncology#ClinicalTrials#ASCO2024#CancerResearch
WOW! In the past month, our MyCural community has grown stronger than ever, reaching over 12,000 people on LinkedIn and welcoming more than 100 new followers. Thank you for being part of our journey! If you know people in your network who would find our mission interesting, please tag them in the comment section!
Here's a brief recap of the impactful work we're doing at MyCural:
🔬 Our Mission: At MyCural, we're dedicated to developing groundbreaking cancer therapies specifically designed for patients with high-risk tumors.
👩🔬 Two Decades of Research: Over the last twenty years, our relentless cancer research efforts have yielded potential candidate drugs that target the elusive "undruggable" MYC, a key driver in over 50% of all cancers.
🚀 Revolutionizing MYC Drug Discovery: Our innovative methods are revolutionizing MYC drug discovery, paving the way for breakthroughs in targeted cancer therapies.
💡 Transforming Challenges: Tackling the unique challenge of developing therapy for the MYC protein, we're overcoming obstacles associated with its disordered structure—a roadblock for conventional drug design.
🌍 Our Vision: MyCural aspires to be a global leader in the field, pushing boundaries and bringing hope to patients where anti-MYC therapy has never succeeded before.
#MyCural#CancerInnovation#ResearchMilestones#FutureOfHealthcare
Innovation has significantly accelerated over the last several years so identifying new partnerships which help us to stay at the forefront of cancer research and development are an important part of our strategy. In this article for @BioPharma Dealmakers, Polly Brown discusses the important role our business development team plays in helping achieve our ambition- the pursuit of cures. These partnerships, in conjunction with our internal efforts, are critical for continuing expand our early oncology portfolio and allow us to bring the best medicines to patients
Today, we’re seeing science and innovation in oncology progressing faster than ever before. These exciting advances are driving the continuous evolution of treatments and helping to redefine cancer care.
At AstraZeneca we have built one of the strongest oncology portfolios and pipelines in the industry with one ambitious goal in mind: eliminating cancer as a cause of death. Partnering with external innovators from across science and technology is critical to achieving this ambition.
In a recent article with Biopharma Dealmakers, Craig Maxwell and I discuss the importance of dealmaking in pursuit of transformational cancer outcomes, and how we assess external opportunities.
Our approach to dealmaking is as robust as our approach to drug development. We’re laser focused on looking for today’s
pioneering therapies, programmes or technologies that have the potential to be part of tomorrow’s transformational regimens. Read our article to find out more: https://lnkd.in/e8v9z2Jk#oncology#researchanddevelopment#pharmapartnering
Life science scouting & licensing
1moGood to see Merck Group , M Ventures and Cancer Research Horizons working together to improve cancer outcomes for patients. Annett Duemmler Lorna Ravenhill